https://www.avient.com/investor-center/news/avient-provides-third-quarter-2020-performance-update
Special items, before tax(1)
1)
Rose, Vice President, Corporate Communications, Avient Corporation, +1 440-930-3162, kyle.rose@avient.com
https://www.avient.com/investor-center/news/avient-announces-third-quarter-2024-results
1)
1)
1)
https://www.avient.com/investor-center/news/polyone-announces-first-quarter-2019-results
Attachment 1
Special items (1)
1)
https://www.avient.com/investor-center/news/polyone-announces-third-quarter-2017-results
Attachment 1
Special items (1)
1)
https://www.avient.com/investor-center/news/polyone-announces-first-quarter-2017-results
Attachment 1
Special items (1)
1)
https://www.avient.com/investor-center/news/polyone-announces-first-quarter-2020-results
Attachment 1
Special items (1)
1)
https://www.avient.com/products/polymer-colorants/solid-color-masterbatches/oncolor-ul-94-colorants
Get Help Now
+1-866-737-2066
V-0, V-1, V-2 and 5VA/5VB ratings for more than 200 specific engineering resins
https://www.avient.com/investor-center/news/polyone-announces-promotion-robert-t-bindner-president-performance-products-solutions
Investor Relations Contact: Joe Di Salvo, Vice President, Investor Relations, PolyOne Corporation, +1 440-930-1921, giuseppe.disalvo@avient.com; Media Contact: Kyle G.
Rose, Vice President, Corporate Communications, PolyOne Corporation, +1 440-930-3162, kyle.rose@avient.com
https://www.avient.com/investor-center/news/polyone-appoints-walter-ripple-vice-president-sustainability-joins-alliance-end-plastic-waste-founding-member
Investor Relations Contact: Joe Di Salvo, Vice President, Investor Relations, PolyOne Corporation, +1 440-930-1921, giuseppe.disalvo@avient.com; Media Contact: Kyle G.
Rose, Vice President, Corporate Communications, PolyOne Corporation, +1 440-930-3162, kyle.rose@avient.com
https://www.avient.com/products/polymer-colorants/healthcare-colorants/mevopur-healthcare-bio-based-polymer-solutions
Get Help Now
+1-866-737-2066
Raw materials tested to ISO 10993-1, USP and (class VI), USP , European Pharmacopeia monographs 3.1.3 and 3.1.5, ICH Q3D